Skip to main content

Table 1 Clinicopathological characteristics of patients with invasive BrCa (N = 206)

From: Profiling the expression of pro-metastatic genes in association with the clinicopathological features of primary breast cancer

Variable Total patients (n) The relative frequency (%) P-value*
Age at diagnosis (year)
 Mean ± S.D. 46.65 ± 8.61   
 < 48 117 56.8 0.051
 ≥ 48 89 43.2  
Age at first pregnancy (year)
 Mean ± S.D. 22.11 ± 4.86   
 < 24 120 60.6 0.003
 ≥ 24 78 39.4  
Age at menopause (year)
 Mean ± S.D. 47.86 ± 4.73   
 Post-menopause 69 33.5 <0.001
 Pre-menopause 137 66.5  
Age at menarche (year)
 Mean ± S.D. 13.52 ± 1.36   
 < 13 40 19.9 <0.001
 ≥ 13 161 80.1  
Tumor type
 IDC 172 92.0 <0.001
 Others 15 8.0  
Tumor size (cm)
 Mean ± S.D. 2.96 ± 1.35   
 T1 (size ≤ 2) 59 31.7 <0.001
 T2 (2 < size ≤ 5) 114 61.3  
 T3 (size > 5) 13 7.0  
Histologic grade
 I 39 20.9 <0.001
 II 126 67.4  
 III 22 11.7  
Axillary lymph node metastasis    
 Negative 64 34.8 <0.001
 Positive 120 65.2  
Tumor stage    
 I 55 30.4 <0.001
 II 119 65.7  
 III 7 3.9  
ER
 Negative 23 12.7 <0.001
 Positive 158 87.3  
PR
 Negative 27 14.9 <0.001
 Positive 154 85.1  
HER2
 Negative 144 79.6 <0.001
 Positive 37 20.4  
Molecular subtype
 Luminal A (ER ± , PR ± , and HER2-) 135 74.6 <0.001
 Luminal B (ER ± , PR ± , and HER2 +) 23 12.7  
 HER2 rich (ER-, PR-, and HER2 +) 14 7.7  
 Triple-negative (ER-, PR-, and HER2-) 9 5.0  
  1. The statistically significant finding was shown in italics (P < 0.05)
  2. N number, S.D. standard deviation, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IDC invasive ductal carcinoma
  3. *The P-value was obtained by the Chi square test.
  4. Some missing existed in demographic and clinicopathologic data